Effects of dexlansoprazole mr, a novel dual delayed release formulation of a proton pump inhibitor, on plasma gastrin levels in healthy subjects

Journal of Clinical Pharmacology

Volumn 49, Issue 4, 2009, Pages 444-454

  Zhang, Weijiang ^a   Wu, Jingtao ^a,b   Atkinson, Stuart N ^a,b  

^a TAKEDA PHARMACEUTICALS   (United States)

^b Takeda Global Research and Development Center   (United States)

Author keywords

Dexlansoprazole; Gastrin; Gastroesophageal reflux disease (GERD); Proton pump inhibitor

Indexed keywords

DEXLANSOPRAZOLE; GASTRIN; LANSOPRAZOLE; PROTON PUMP INHIBITOR; TAK 390; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DELAYED RELEASE FORMULATION; DIARRHEA; DIET RESTRICTION; DOUBLE BLIND PROCEDURE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG FATALITY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ELECTROCARDIOGRAM; FEMALE; GASTRIN BLOOD LEVEL; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; HUMAN EXPERIMENT; INFLAMMATION; LABORATORY TEST; MALE; MAXIMUM PLASMA CONCENTRATION; NAUSEA AND VOMITING; NORMAL HUMAN; NOSE CONGESTION; OPEN STUDY; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT DISEASE; SIDE EFFECT; TIME TO MAXIMUM PLASMA CONCENTRATION; UPPER ABDOMINAL PAIN; VITAL SIGN;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; ADOLESCENT; ADULT; CHEMISTRY, PHARMACEUTICAL; CROSS-OVER STUDIES; DELAYED-ACTION PREPARATIONS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GASTRINS; HUMANS; MALE; MIDDLE AGED; PROTON PUMP INHIBITORS;

EID: 63849120129     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270008330155     Document Type: Article

References (42)

1. Dekel R., Morse C., Fass R. The role of proton pump inhibitors in gastro-oesophageal reflux disease. Drugs. 2004; 64: 277-295.
2. Richardson P., Hawkey CJ, Stack WA Proton pump inhibitors: pharmacology and rationale for use in gastrointestinal disorders. Drugs. 1998; 56: 307-335.
3. Welage LS, Berardi RR Evaluation of omeprazole, lansoprazole, pantoprazole, and rabeprazole in the treatment of acid-related diseases. J Am Pharm Assoc (Wash). 2000; 40: 52-62.
4. Castell DO, Richter JE, Robinson M., Sontag SJ, Haber MM Efficacy and safety of lansoprazole in the treatment of erosive reflux esophagitis. The Lansoprazole Group. Am J Gastroenterol. 1996; 91: 1749-1757.
5. Chiba N., De Gara CJ, Wilkinson JM, Hunt RH Speed of healing and symptom relief in grade II to IV gastroesophageal reflux disease: a meta-analysis. Gastroenterology. 1997; 112: 1798-1810.
6. DeVault KR, Castell DO Updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease. Am J Gastroenterol. 2005; 100: 190-200.
7. Hatlebakk JG, Berstad A., Carling L., et al. Lansoprazole versus omeprazole in short-term treatment of reflux oesophagitis: results of a Scandinavian multicentre trial. Scand J Gastroenterol. 1993; 28: 224-228.
8. Maton PN, Vakil NB, Levine JG, Hwang C., Skammer W., Lundborg P. Safety and efficacy of long term esomeprazole therapy in patients with healed erosive oesophagitis. Drug Saf. 2001; 24: 625-635.
9. Holloway RH, Dent J., Narielvala F., Mackinnon AM Relation between oesophageal acid exposure and healing of oesophagitis with omeprazole in patients with severe reflux oesophagitis. Gut. 1996; 38: 649-654.
10. Peghini PL, Katz PO, Bracy NA, Castell DO Nocturnal recovery of gastric acid secretion with twice-daily dosing of proton pump inhibitors. Am J Gastroenterol. 1998; 93: 763-767.
11. Peghini PL, Katz PO, Castell DO Ranitidine controls nocturnal gastric acid breakthrough on omeprazole: a controlled study in normal subjects. Gastroenterology. 1998; 115: 1335-1339.
12. Eissele R., Rosskopf B., Koop H., Adler G., Arnold R. Proliferation of endocrine cells in the rat stomach caused by drug-induced achlorhydria. Gastroenterology. 1991; 101: 70-76.
13. Ekman L., Hansson E., Havu N., Carlsson E., Lundberg C. Toxicological studies on omeprazole. Scand J Gastroenterol Suppl. 1985; 108: 53-69.
14. Hakanson R., Tielemans Y., Chen D., et al. The biology and pathobiology of the ECL cells. Yale J Biol Med. 1992; 65: 761-774; discussion 827-769.
15. Poynter D., Selway SA Neuroendocrine cell hyperplasia and neuroendocrine carcinoma of the rodent fundic stomach. Mutat Res. 1991; 248: 303-319.
16. Aly A., Shulkes A., Baldwin GS Gastrins, cholecystokinins and gastrointestinal cancer. Biochim Biophys Acta. 2004; 1704: 1-10.
17. Bardhan KD, Cherian P., Bishop AE, et al. Pantoprazole therapy in the long-term management of severe acid peptic disease: clinical efficacy, safety, serum gastrin, gastric histology, and endocrine cell studies. Am J Gastroenterol. 2001; 96: 1767-1776.
18. Bell N., Karol MD, Sachs G., Greski-Rose P., Jennings DE, Hunt RH Duration of effect of lansoprazole on gastric pH and acid secretion in normal male volunteers. Aliment Pharmacol Ther. 2001; 15: 105-113.
19. Freston JW, Rose PA, Heller CA, Haber M., Jennings D. Safety profile of lansoprazole: the US clinical trial experience. Drug Saf. 1999; 20: 195-205.
20. Muller P., Dammann HG, Leucht U., Simon B. Human gastric acid secretion following repeated doses of AG-1749. Aliment Pharmacol Ther. 1989; 3: 193-198.
21. Sanders SW, Tolman KG, Greski PA, Jennings DE, Hoyos PA, Page JG The effects of lansoprazole, a new H+,K(+)-ATPase inhibitor, on gastric pH and serum gastrin. Aliment Pharmacol Ther. 1992; 6: 359-372.
22. Van Rensburg CJ, Honiball PJ, Van Zyl JH, et al. Safety and efficacy of pantoprazole 40 mg daily as relapse prophylaxis in patients with healed reflux oesophagitis-a 2-year follow-up. Aliment Pharmacol Ther. 1999; 13: 1023-1028.
23. Warrington S., Baisley K., Boyce M., Tejura B., Morocutti A., Miller N. Effects of rabeprazole, 20 mg, or esomeprazole, 20 mg, on 24-h intragastric pH and serum gastrin in healthy subjects. Aliment Pharmacol Ther. 2002; 16: 1301-1307.
24. Williams MP, Blanshard C., Millson C., Sercombe J., Pounder RE A placebo-controlled study to assess the effects of 7-day dosing with 10, 20 and 40 mg rabeprazole on 24-h intragastric acidity and plasma gastrin in healthy male subjects. Aliment Pharmacol Ther. 2000; 14: 691-699.
25. Williams MP, Sercombe J., Hamilton MI, Pounder RE A placebo-controlled trial to assess the effects of 8 days of dosing with rabeprazole versus omeprazole on 24-h intragastric acidity and plasma gastrin concentrations in young healthy male subjects. Aliment Pharmacol Ther. 1998; 12: 1079-1089.
26. Sharma B., Axelson M., Pounder RP, et al. Acid secretory capacity and plasma gastrin concentration after administration of omeprazole to normal subjects. Aliment Pharmacol Ther. 1987; 1: 67-76.
27. Klinkenberg-Knol EC, Nelis F., Dent J., et al. Long-term omeprazole treatment in resistant gastroesophageal reflux disease: efficacy, safety, and influence on gastric mucosa. Gastroenterology. 2000; 118: 661-669.
28. Solcia E., Fiocca R., Havu N., Dalvag A., Carlsson R. Gastric endocrine cells and gastritis in patients receiving long-term omeprazole treatment. Digestion. 1992; 51: 82-92.
29. Freston JW, Borch K., Brand SJ, et al. Effects of hypochlorhydria and hypergastrinemia on structure and function of gastrointestinal cells: a review and analysis. Dig Dis Sci. 1995; 40: 50S - 62S.
30. Genta RM, Rindi G., Fiocca R., Magner DJ, D'Amico D., Levine DS Effects of 6-12 months of esomeprazole treatment on the gastric mucosa. Am J Gastroenterol. 2003; 98: 1257-1265.
31. Klinkenberg-Knol EC, Festen HP, Jansen JB, et al. Long-term treatment with omeprazole for refractory reflux esophagitis: efficacy and safety. Ann Intern Med. 1994; 121: 161-167.
32. Lamberts R., Brunner G., Solcia E. Effects of very long (up to 10 years) proton pump blockade on human gastric mucosa. Digestion. 2001; 64: 205-213.
33. Robertson DJ, Larsson H., Friis S., Pedersen L., Baron JA, Sorensen HT Proton pump inhibitor use and risk of colorectal cancer: a population-based, case-control study. Gastroenterology. 2007; 133: 755-760.
34. Yang YX, Hennessy S., Propert K., Hwang WT, Sedarat A., Lewis JD Chronic proton pump inhibitor therapy and the risk of colorectal cancer. Gastroenterology. 2007; 133: 748-754.
35. Zhang W., Wu J., Atkinson SN Pharmacokinetics, pharmacodynamics, and safety evaluation of a single and multiple 60 mg, 90 mg, and 120 mg oral doses of modified-release Dexlansoprazole (Dexlansoprazole MR) and 30 mg oral doses of lansoprazole in healthy subjects [abstract]. Gastroenterology. 2007; 132: A487.
36. Sanduleanu S., Stridsberg M., Jonkers D., et al. Serum gastrin and chromogranin A during medium- and long-term acid suppressive therapy: a case-control study. Aliment Pharmacol Ther. 1999; 13: 145-153.
37. Jansen JB, Klinkenberg-Knol EC, Meuwissen SG, et al. Effect of long-term treatment with omeprazole on serum gastrin and serum group A and C pepsinogens in patients with reflux esophagitis. Gastroenterology. 1990; 99: 621-628.
38. Lind T., Cederberg C., Forssell H., Olausson M., Olbe L. Relationship between reduction of gastric acid secretion and plasma gastrin concentration during omeprazole treatment. Scand J Gastroenterol. 1988; 23: 1259-1266.
39. Brunner G., Creutzfeldt W. Omeprazole in the long-term management of patients with acid-related diseases resistant to ranitidine. Scand J Gastroenterol Suppl. 1989; 166: 101-105; discussion 111-103.
40. Lamberts R., Creutzfeldt W., Struber HG, Brunner G., Solcia E. Long-term omeprazole therapy in peptic ulcer disease: gastrin, endocrine cell growth, and gastritis. Gastroenterology. 1993; 104: 1356-1370.
41. Koop H., Arnold R. Long-term maintenance treatment of reflux esophagitis with omeprazole: prospective study in patients with H2-blocker-resistant esophagitis. Dig Dis Sci. 1991; 36: 552-557.
42. Hirschowitz BI, Mohnen J., Shaw S. Long-term treatment with lansoprazole for patients with Zollinger-Ellison syndrome. Aliment Pharmacol Ther. 1996; 10: 507-522.